Drugs / CNM-Au8
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 26 trials | ||||||
| Phase 2 | NCT05299658 | Nov 2021 → Jun 2026 overdue | amyotrophic lateral sclerosis | Clene Nanomedicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03843710 | Mar 2020 → Feb 2022 | amyotrophic lateral sclerosis | Clene Nanomedicine | Withdrawn | No outcome recorded |
| Phase 2 | NCT04098406 | Dec 2019 → Jul 2021 | amyotrophic lateral sclerosis | Clene Nanomedicine | Completed | No outcome recorded |
| Phase 2 | NCT03815916 | Dec 2019 → Jun 2021 | Parkinson disease | Clene Nanomedicine | Completed | No outcome recorded |
| Phase 2 | NCT03993171 | Dec 2019 → May 2025 | multiple sclerosis | Clene Nanomedicine | Completed | No outcome recorded |
| Phase 2 | NCT03536559 | Nov 2018 → Apr 2022 | optic neuritis, relapsing-remitting multiple sclerosis | Clene Nanomedicine | Terminated | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT04626921 | Oct 2020 → May 2023 | multiple sclerosis | Clene Nanomedicine | Completed | No outcome recorded |
| Phase 2/3 | NCT04414345 | Jul 2020 → Apr 2022 | amyotrophic lateral sclerosis | Merit E. Cudkowicz, MD | Completed | No outcome recorded |
| Phase 2/3 | NCT04297683 | Jun 2020 → Jul 2027 expected | amyotrophic lateral sclerosis | Merit E. Cudkowicz, MD | Recruiting | No outcome recorded |
| Phase not stated3 trials | ||||||
| — | NCT06408727 | — | amyotrophic lateral sclerosis | Clene Nanomedicine | Temporarily not available | No outcome recorded |
| — | NCT05281484 | — | amyotrophic lateral sclerosis | Clene Nanomedicine | No longer available | No outcome recorded |
| — | NCT04081714 | — | multiple sclerosis | Clene Nanomedicine | Temporarily not available | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNM-Au8 | “CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water with...” NCT03815916 ↗10“CNM-Au8 is a dark red/purple-colored liquid formulation consisting of a stable suspension of faceted clean surfaced elemental gold nanocrystals in buffered deionized water” NCT03843710 ↗ “CNM-Au8® is a catalytically-active gold nanocrystal neuroprotective agent” PMID 37396808 ↗ Jun 2023 |
| Known as | gold nanocrystals | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03993171 ↗ |
| Modality | Other / unclassified | “stable suspension of faceted clean surfaced elemental gold nanocrystals” NCT03843710 ↗ |
| Route | Oral | “The drug product is formulated to be taken orally” NCT03536559 ↗ |